WALTHAM, MA • 2021-11-30

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

5 min to read

Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact
BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director